FGAM
SRPT icon

Financial Gravity Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Financial Gravity Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$126 – 1744
2024
Q1 		$126 Buy
+1
New +$122 ﹤0.01% 956
2021
Q2 		– Hold
0
– – – 426

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Financial Gravity Asset Management's SRPT Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 1 share — an estimated $126 sold.

Financial Gravity Asset Management first reported a position in SRPT in Q1 2024 and held it in 1 quarter. The position peaked at $126 in Q1 2024. 485 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 1 Sarepta Therapeutics share in Q2 2024, an estimated $126.
  • Financial Gravity Asset Management first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 1 quarter.
  • Financial Gravity Asset Management's Sarepta Therapeutics position peaked at $126 in Q1 2024.
  • 485 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.